Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Transformed Chronic Lymphocytic Leukemia: early-phase trial registry
8 of 9 indexed Recurrent Transformed Chronic Lymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 8 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Recurrent Transformed Chronic Lymphocytic Leukemia: 9 US clinical trials tracked, 8 recruiting.
Recurrent Transformed Chronic Lymphocytic Leukemia is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 3 of these trials.
Enrollment posture brief
Registry condition recurrent-transformed-chronic-lymphocytic-leukemia
OPEN 8 | RECR 89% | LATE 0 | EARLY 9 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Spinal Cord Injury (89% recruiting · 9 trials)
Recurrent Transformed Chronic Lymphocytic Leukemia lists 8 open slots (89% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Transformed Chronic Lymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Transformed Chronic Lymphocytic Leukemia is recruiting above its size-band peers.
8 of 9 indexed trials (88.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Transformed Chronic Lymphocytic Leukemia research.
City of Hope Medical Center accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Transformed Chronic Lymphocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 25 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.
-
Recurrent Transformed Chronic Lymphocytic Leukemia research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Sumithira Vasu
NCT05418088
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
NCT05672251
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
NCT06191887
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic
NCT04892277
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT07166419
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Aseel Alsouqi
NCT05873712
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
City of Hope Medical Center
NCT06735664
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
City of Hope Medical Center
NCT05672173
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
M.D. Anderson Cancer Center
NCT02846623
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Transformed Chronic Lymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Transformed Chronic Lymphocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Transformed Chronic Lymphocytic Leukemia page
9 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Recurrent Transformed Chronic Lymphocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Recurrent Transformed Chronic Lymphocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Transformed Chronic Lymphocytic Leukemia condition card totals 9 registered trials; most-linked intervention Biospecimen Collection; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.